Abstract-Direct intracerebral administration of N-methyl-D-aspartate typically produces focal brain injury. (+)-5-Methyl-lo, 1 l-dihydro-SH-dibenzo [u&yclohepten-5,10-immine maleate (MK-801), a noncompetitive N-methyl-D-aspartate antagonist, can protect against IV-methyl-u-aspartate-mediated brain injury when administered shortly before or after an intracerebral injection of N-methyl-D-aspartate.
peritoneally 24 h prior to a unilateral intrastriatal N-methyl-n-aspartate injection, N-methyl-n-aspartatemediated brain injury is paradoxically enhanced. The severity of resulting brain injury is B-25% greater in groups that received MK-801 in comparison with saline-treated controls (P < 0.001, linear regression analysis). In contrast, the severity of brain injury resulting from intrastriatal injection of the glutamate agonist quisqualate is not altered by a similar 24 h MK-801 pretreatment. binding to the phencyclidine site associated with the N-methyl-naspartate receptor was reduced by 6@-80% in all brain regions examined (P <O.OOl). Quisqualate-sensitive [3H]glutamate binding was not altered by a 2 h MK-801 pretreatment. In animals that received a 24 h MK-801 pretreatment, ~-methyl-~~~r~t~~nsitive rH]glutamate binding remained elevated (29% increase in CA! and CA3, P c 0.05), [3H]~-l-(2-~ienyl~clohexyl-3,~ piperidine binding was still suppressed (40% reduction in CA1 and CA3. P < 0.05) and quisqualatesensitive [3H]glutamate binding was reduced by I5-20% in area CA3 and in the corpus striatum (P < 0.05, ANOVA).
The results suggest that MK-801 induces rapid and persistent up-regulation of N-methyl-D-aspartate receptors and sensitizes the brain to N-methyl-D-aspartate-induced injury as the level of MK-801 in the brain declines. The observations provide new information about regulation of the N-methyl-D-aspartate receptor complex and may be relevant in the analysis of the neuroprotective properties of phencyclidine receptor ligands.
Intrastriatal injection of ~-methyl-D-aspar~te
(NMDA), an analog of the excitatory n~urotransmit-ter glutamate, typically produces focal brain injury in rodents.4-'o~'8~20~2'b~35 The neurotoxicity appears to be mediated by the NMDA receptor-channel complex and is prevented by specific antagonists selective for this site.5~"~"~20~2' Study of this model of neurotoxicity may be relevant to development of novel therapeutic strategies for several neurological dis§To whom correspondence should be addressed. 
EXPERIMENTAL PROCEDURES

Experimenral prorocols
To determine the effect of 24 h MK-801 pretreatment on NMDA-mediated brain injury, postnatal day (PND) 6 rats (Sprague-Dawley, Charles River) were administered 1 mg/ kg (in 0.05 ml phosphate-buffered saline) MK-801 i.p. or an equivalent volume saline. Twenty-four hours later amounts of NMDA varying from 5 to 25 nmol were injected into the right striatum. Animals were killed on PND 12. The number of animals used per group (n = saline-treated. MK-801-treated) were: 5 nmol NMDA (n = 9, 8); IO nmol NMDA (n = 16. 16); 17 nmol NMDA (n = 8, 9); 25 nmol NMDA (II = 20, 17) . Experiments were performed with PND 6-7 age animals because this represents an important developmental time point with regard to the ontogeny of excitatory amino acid (EAA) receptors and EAA neurotoxicity.'x To examine, in greater detail, the effect of the time interval between MK-801 pretreatment and intrastriatal injection of NMDA on the severity of NMDA-induced brain injury, PND 7 rats were administered 1 mg/kg MK-801 at five time intervals before unilateral intrastriatal injection of 25 nmol NMDA. Time intervals (in hours) were: 0.5. 2, 6, 12, 24 (n = 7/group); NMDA-injected controls received saline (n = 13). Animals were killed on PND 12. The extent of damage produced by NMDA in saline-treated animals at these time intervals did not differ among groups and all saline-treated, NMDA-injected controls were pooled for statistical analysis (P = non-significant, one-way ANOVA).
To determine whether the enhanced toxicity of NMDA produced by MK-801 pretreatment could be blocked by an NMDA antagonist, two groups of PND 6 rats received either 1 mg/kg MK-801 (n = 9) or saline (n = I I) and 24 h later pups in both groups were injected intrastriatally with 25 nmol NMDA. Fifteen minutes later all animals received a second injection of MK-801 (I me/kg). Animals were decapitated on PND 12.
To determine if the enhanced toxicity of NMDA produced by 24 h MK-801 pretreatment was the result of adverse systemic effects such as hypotension, respiratory depression, decreased food intake or prolonged sedation, chloral hydrate was used to produce a similar depth and duration of anesthesia as I mg/kg MK-801. PND 6 rats received two i.p. injections of either chloral hydrate (100 mg/kg each; n = 6) or saline (n = 8). Twenty-four hours later 17 nmol of NMDA was injected into the right striatum.
To determine if the ability of hlK-801 to enhance brain injury was selective for NMDA-induced damage. intrastriatal injections of the neurotoxic glutamate agonist quisqualate were carried out in rats that received MK-801 24 h earlier. PND 6 rats received I mg/kg MK-801 (n = IO) or saline (n = 10). Twenty-four hours later. IOOnmol quisqualate was injected into the right striatum. Animals were decapitated on PND 12. Administration of larger doses of quisqualate (> 100 nmol) that produce a level of brain injury equivalent to intermediate doses of NMDA (l&25 nmol) was limited by the solubility of quisqualate. the injection volume (0.5 ~1). and seizure related increased mortality rate.
Quantitative receptor autoradiography was used to examine the hypothesis that MK-801-induced alterations in EAA receptor binding characteristics may be associated with the enhanced toxicity of NMDA produced by MK-801 pretreatment. PND 6 (n = 6) and PND 7 (n = 6) rats received either I mgikg MK-801 (n =3/age) or saline (n = 3/age). i.p. Twenty-four or two hours later the rats were decapitated. Three receptor assays were used to assess NMDA. quisqualate and PCP selective receptors as described below. Scatchard analysis of NMDA receptor binding was carried out in an additional set of PND 6 rats treated with I mg!kg (II = 3) or saline (n = 3) and killed 2 h later.
intracerehral injections
Injections were performed as previously described ' "' Brieflv, PND 7 rats were anesthetized with ether and a midline scalp incision was made to expose the calvarium. Pups were positioned in a plaster of Paris mold of the head and body. lntracerebral stereotaxic injections were performed with a 26gauge, beveled tip. Hamilton syringe using a Kopf small animal apparatus. All intracerebral injections were made in the posterior striatum. Using bregma as a landmark, injection site coordinates were AP 2.0 mm. L 2.5 mm. at a depth of 4 mm from the dura. The needle was left in place for 2 min following injection to limit leakage. NMDA and quisqualate were dissolved in 0.01 M Tris buffer. pH 7.4. Pups received varying amounts of NMDA or quisqualate intrastriatally in a volume of 0.5 ~1. The scalp was sutured with 6-O nylon suture. Rats were subsequently placed under a warming lamp set to maintain a 37'C body temperature, for 2 h. Pups were then returned to their mother, Five days later. on PND 12. animals were killed by decapitation.
Quant+carion of twain injury hy comparison o/ cerrbrul hemisphere weights
The forebrain was separated from the cerebellum and brainstem using a razor blade. The two cerebral hemispheres were separated and weighed. Hemisphere weight disparities were compared for each animal using the formula lOO* (C -1)/C = per cent damage, a value that reflects the severity of damage of the injected (I) cerebral hemisphere relative to the contralateral (C) hemisphere. This is an accurate and sensitive method for quantification of brain injury in perinatal rats'0-2'a and the size of the contralateral hemisphere did not differ from controls. Values presented are mean f S.E.M.
A second value, per cent protection was calculated to compare the severity of brain damage present in MK-801-treated animals relative to saline-treated controls:
per cent protection = lOO* 
Auroradiograph,~
Brains were removed and rapidly frozen on dry ice. Horizontal frozen brain sections were thaw-mounted onto gelatin-coated slides. ['HIGlutamate (Amersham) was used to label NMDA-sensitive and quiqualate-sensitive glutamate receptors, and ['H]N-I-(2-thienyl)cyclohexyl-3,4-piperidine [ZH]TCP (New England Nuclear) was used to label PCP receptors in adjacent sections from saline-and MK-801-treated animals as previously described.2~R~9~ '4-2h Briefly All sections were placed in X-ray cassettes with appropriate standards, apposed to 3H-sensitive Ultrafilm, exposed for three to six weeks, developed and analysed densitomet&ally using a micr~omputer-bald video densitometer system;9J6 (Imaging Research, St Catherines, Ontario). Ten readings were taken bilaterally and averaged for each of four brain regions examined; CA1 and CA3 hippocampal subfields (stratum radiatum laminae), corpus striatum, and cingulate cortex.
Statistical analysis
A micr~omputer-~~ software program (Systat) was used for statistical analysis. Linear regression analysis was used to test the effect of 24 h MK-801 pretreatment on the severity of NMDA-mediated brain injury; a simultaneous test of slope and intercept for differences between lines in the linear phase was used since a linear trend existed and data points were not independent. ANOVA was used to compare the effect of the time interval between MK-801 treatment and intrastriatal injection of NMDA on the severity of NMDA-mediated brain injury and was used to determine the effect of MK-801 pretreatment on NMDA, PCP and quisqualate receptor binding. All other tests were independent r-tests unless stated otherwise.
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RESULTS
Neurotoxicity
In rats treated with MK-801 24 h prior to NMDA injection, the size of the NMDA lesion was visibly larger than that produced by the same amount of NMDA in saline-treated rats (Fig. IA) . Comparison of Nissl-stained coronal brain sections from rats treated with either MK-801 or saline and injected with NMDA demonstrates similar results (Fig, 1B) . Histograms comparing the severity of brain injury produced by unilateral intrastriatal injection of increasing amounts of NMDA (5, 10, 17, 25 nmol) in rats that received i.p. injections of either 1 mg/kg MK-801 or saline 24 h earlier are presented in Fig. 2 . The severity of brain injury as assessed by disparities in cerebral hemisphere weights was greater in groups that received MK-801 24 h earlier compared with saline-treated groups (regression analysis, P < 0.00 1, simultaneous test for slope and intercept). The mortality rate in saline-treated animals was 0% in groups that received 17 nmol of NMDA or less and was 5% in groups that received 25 nmol NMDA. Mortality rates in groups that received MK-801 24 h before Fig. 1 . Comparison of NMDA-induced brain injury in whole brains (A) and in corresponding Nissl-stained coronal brain sections (B) from rats that received either 1 mg/kg MK-801 or saline, i.p., 24 h before unilateral intrastriatal injection of 25nmol NMDA on PND 7. MK-801 and saline were administered on PND 6. Animals were killed five days after NMDA injection. The whole brain and tissue section on the right are representative of rats that received MK-801 whereas the ones on the left are representative of saline-treated animals. The increased severity of the NMDA-induced lesion is evident in brains from MK-801-treated rats in comparison with saline-treated controls. NMDA were slightly greater: IS%, 12 .5%, and 0% in groups that received 25, 17, and 10 or less nmol of NMDA, respectively. Administration of MK-801 (1 mg/kg) in the absence of NMDA produced no signs of neurotoxicity when assessed by light microscopy five days later (n = 5).
In contrast to the effect of 24 h MK-801 pretreatment on the severity of NMDA-induced brain damage, administration of MK-801 at intervals up to 12 h before intrastriatal injection of NMDA significantly reduced the degree of resulting brain injury, P < 0.001. ANOVA, MK-Sol-treated vs salinetreated (Fig. 3) . The degree of protection against NMDA toxicity produced by MK-801 was 98.9 _4 2.8% in animals treated with MK-801 0.5 h prior to injection of NMDA and declined to 72.5 + 2.6%, 65. I _+ 6.4% and then 54.8 + 3.1% protection when the time interval was extended to 2, 6 or 12 h, respectively. Mortality rate in the saline-treated group was 15% and was 0% in animals treated with MK-801 0.5-12 h before injection of NMDA.
The enhanced toxicity of NMDA produced by 24 h MK-801 pretreatment was blocked by a second injection of MK-801 15 min after intrastriatal injection of 25 nmol NMDA (Table I in MK-801-pretreated animals that received a second post-NMDA injection of MK-801 (n = 9). There was no mortality in these two groups of animals. The enhancement of NMDA-mediated neurotoxicity is probably not related to a non-specific effect of The enhanced toxicity of NM.DA produced by MK-801 pretreatment was CompIeteIy blocked by a second injection of MK-801 shortly after the intrastriatal injection of NMDA. *P < 0.01 vs saline, NMDA treatment, independent r-teds. **P < 0.001 vs saline, NMDA treatment. ***P < 0.001 vs MK-801, NMDA treatment. PMK-801 (I mg/kg) and saline were administered i.p. in 0.05 ml. SNMDA (25 nmol/OS ml) was injected intrastriatally 24 h after PND 6 treatment. MK-801 (I mgjkg) was administered i.p. 15 min after NMDA injections. §Per cent damage refers to the decrease in the weight of the injected (I) relative to the contralateral (C) cerebral hemispheres using the equation:
per cent damage = lOO* (C -1)/C. /In = number of surviving animals. Chloral hydrate at doses that reproduced the duration and depth of sedation produced by 1 mg/kg MK-801 did not alter NMDA toxicity when administered 24 h earlier.
tChlora1 hydrate (100 mg/kg per dose) and saline were administered i.p. in 0.05 ml. SNMDA (17 nmol/0.5 ~1) was injected intrastriatally 24 h after PND 6 treatment. §Per cent damage refers to the decrease in the weight of the injected (I) relative to the contralateral (C) cerebral hemisphere using the equation:
per cent damage = 100* (C -1)/C.
[(n = number of surviving animals.
prolonged sedation.
The severity of NMDAmediated brain injury was not altered by pretreatment with chloral hydrate at doses that produced a similar depth and duration of sedation as that produced by 1 mg/kg MK-801 (Table 2 ). In animals that received two i.p. injections of chloral hydrate (100 mg/kg each) the severity of brain damage produced by 17 nmol NMDA was 15.85 f 2.91% (n = 6) with a corresponding value of 16.22 + 2.51% in animals that received two i.p. injections of saline (n = 8). All animals survived.
The selectivity of the effect of 24 h MK-801 pretreatment on NMDA specific damage was demonstrated by the observation that the severity of quisqualate-mediated brain injury was not altered by 24 h MK-801 pretreatment ( Table 3 ). The severity of brain damage (per cent damage, mean+S.E.M.) The ability of MK-801 to enhance the severity of NMDAmediated brain injury appears to be s&ctive, since administration of MK-801 24 h orior to intrastriatal injection of quisqualate did not *alter the severity of resulting brain injury. tMK-801 (1 mg/kg) and saline were administered i.p. in 0.05 ml. SQuisqualate (100 nmol/0.5 ~1) was injected intrastriatally 24 h after PND 6 treatment. §Per cent damage refers to the decrease in the weight of the injected (I) relative to the contralateral (C) cerebral hemispheres using the formula:
per cent damage = 100' (C -1)/C. Jln = number of surviving animals.
produced by intrastriatal injection of 100 nmol quisqualate was 7.54 + 1.33% (n = 9) in animals treated with saline and 7.62 &-0.72% (n = 10) in animals treated with MK-801 24 h prior to the injection of quisqualate. One out of 10 animals that received MK-801 24 h prior to injection of quisqualate died whereas all animals survived in the saline-treated group. The use of quisqualate as a control to de&nine the selectivity of the effect of 24 h MK-801 treatment on neurotoxicity is limited due to the low solubility and toxicity of quisqualate at this age. For these reasons, doses of quisqualate that were equipotent with the doses of NMDA used could not be tested. Therefore, it is possible that toxicity resulting from equipotent doses of a quisqualate receptor agonist may be altered by 24 h MK-801 pretreatment as may be suggested by the reduction of quisqualate receptor binding produced by 24 h MK-801 pretreatment (see below).
Autoradiography
In PND 7 rats treated with MK-801 (1 mg/kg) 2 h prior to being killed, NMDA-sensitive ['HIglutamate binding in the CA1 stratum radiatum was increased by 41.5% above saline-treated controls (MK-801-treated, n = 3, 1479 k 73.8 vs saline-treated, n = 3, 1045.5 +_ 31.4 fmol/mg protein, P < 0.001, paired ttest, see Fig. 4 ). In an additional group of PND 6 rats, saturation analysis indicated that the increase in The apparent discrepancy between the maximum number of NMDA binding sites determined directly by saturation analysis and by extrapolation from single concentration studies likely reflects the different age animals used in each study. The animals were six days old in saturation studies and seven days old in single concentration studies. Due_ to the rapid phase of NMDA receptor expression during this period,*lb the number of binding sites would be substantially greater on PND 7 compared with PND 6 as reflected in the present results.
[3H]TCP binding was reduced by 83% in 2-h MK-801-pretreated PND 7 animals compared with saline-treated controls (MK-801-treated, n = 3, 26.2 f 4.9 vs saline-treated, n = 3, 161.3 f 54.9 fmol/mg protein, P < 0.01, paired ttest). In contrast quisqualate-sensitive
[3H]glutamate binding to high affinity receptors was not affected by 2 h MK-801 pretreatment (MK-801-treated, n = 3, 781.9 + 12.9 vs saline-treated, n = 3, 868.6 + 36.9 fmol/mg protein).
In rats that received MK-801 24 h prior to being killed, NMDA-sensitive ['HIglutamate binding remained elevated (Figs 5 and 6 ). Autoradiographic 1 mg/kg MK-801 24 h before they were killed (Fig. 6) . Binding was reduced by 40% in CA1 and CA3 hippocampal subfields with a similar trend in the striatum and cingulate [P c 0.05, MK-801-treated (n = 3) vs saline-treated (n = 3), ANOVA]. Quisqualate-sensitive glutamate binding was reduced in MK-801-treated animals (Fig. 6) . Binding in the CA3 hippocampal subfield and in the corpus striatum was reduced by approximately 15 and 20%, respectively [P < 0.05 for each area, MK-80I-treated (n = 3) vs saline-treated (n = 3), ANOVA]. Binding did not differ si~i~~antly between groups in area CA1 and cingulate.
DISCUSSION
Our results demonstrate that, in addition to the well described neuroprotective effects of MK-801,5.6~16.'7.20 treatment with MK-801 may also sensitize the brain to NMDA receptor-mediated brain injury as levels of the drug decline in the brain. in contrast to the neuroprotective effects of 1 mg/kg of MK-801 when administered 0.5-12 h before intrastriatal injection of 25 nmoi NMDA, extension of this interval to 24 h results in a paradoxical increase in the severity of NMDA-mediated brain injury in comparison with saline-treated, NMDA-injected controls. One possible explanation for the enhanced toxicity of NMDA after 24 h MK-801 pretreatment may be that MK-801 produces adverse metabolic effects related to sedation and reduced intake of milk. However, in rats that received two i.p. injections of chloral hydrate, at doses that resulted in a similar depth and duration of sedation as produced by MK-801, the severity of NMDA-induced brain injury did not differ from that produced in saline-treated controls. Thus it is unlikely that decreased food intake or other adverse systemic effects produced by sedation directly ~ont~buted to the increased severity of injury. The reported neurotoxic properties of MK-801 when administered in vivo are unlikely related to enhanced toxicity of NMDA in animals pretreated for 24 h with MK-801, since the reported pathological changes associated with MK-801 treatment are: small relative to the increased severity of NMDA toxicity, acute, reversible and regionally restricted. *S Also, no histologic signs of neurotoxicity were observed in animals treated with MK-801 alone when assessed six days later. Furthermore, the effect of MK-801 pretreatment was selective for enhancement of NMDA-m~iated brain injury since quisqualate-mediated brain injury was not increased by a similar MK-801 pretreatment. Scatchard analysis of binding at 24h was not examined, the data presented here suggest that the up-regulation of NMDA recognition sites persists up to 24 h. Two hours after MK-801 administration, the levels of MK-801 in the brain are apparently sufficient to block NMDA neurofoxicify despite receptor regulation. The heighfened sensitivity of the brain to NMDA neurotoxjcity found 24 h affer MEL-801 administration may be related to the persistent increased number of NMDA ~co~ition sites after the level of MK-801 in the brain and its neuroprotective e&c% have diminished. Our observation that a second injection of MK-801 shortly after the intrastriatal injection of NMDA completely blocks the enhanced toxicity is consistent with this hypothesis.
Although MK-801 reduces quisqualate-mediated brain damage when administered concurrently?' quisqualate toxicity is unaltered by 24 h MK-801 pretreatment.
Thus, the mechanism underlying enhanced NMDA toxicity appears to be specific rather than a non-selective effect on neuronal metabolism.
The The susceptibility of the brain to NMDA toxicity changes during developmenf. Qur study focused on NMDA-undue ne~otoxicity in PND 7 rats because NMDA-induced neurotoxicify peaks on this day'* and the excitotoxic lesion is we11 characterized at this age. EJ-'~ Compared with adult rats, on PND 7 direct intracerebral injection of NMDA produces a more extensive lesion that is about 60 times larger per dose. Neurophysiologic studies have also shown that NMDA receptars in developing brain are more effective than in adult brain. Whether the acfions of MK-go01 pretreatment on NMDA receptor binding and NMDA toxicity are a general phenomena or restricted to a specific developmen~l period requires additional studies at other developmental time points. However, the ability of PCP-like compounds to increase NMDA-sensitive ~3H]glu~mate binding does not appear to be limited to the developing brain. The dissociative anesthetic ketamine (which acts at the PCP receptor) can also produce a rapid increase in NMDA-sensitive glutamate binding in adult rat brain when administered (100 mg/kg, i.p.) 30 min prior to being killed (Young and Greenamyre, personal ~mmunication).
Whether MK-801 can also enhance the toxicity of MK-801 in the adult brain has not been examined.
The results provide novel info~atjon about NMDA r~eptor~hannel regulation and relate these changes to alterations in the pathophysioio~ of NMDA toxicity. They provide the first evidence that a non-competitive NMDA antagonist, MK-801, Induces a rapid, persistant and selective increase in NMDA-sensitive ['HIglutamate binding and selectively sensitizes the brain to NMDA-mediated brain injury as the neuroprotective effect of the drug declines. The NMDA ~ptor~hannel may participate in a wide range of neurophysiolo~ic and pathophysiofogic processes in both the developing and adult nervous system. Acute admi~stration of MK-801-and PCP-like compounds protects the brain from a variety of insults including physical trauma, hypoxiaischemia, and sustained seizures associated with NMDA receptor overactivation4.i*.~z.~ and these compounds (e.g. MK-801) may have considerable neuroprotective properties in a variety of neurologic disorders.'~7*'3~23~z*~37 However, our results suggest that these compounds may also sensitize the brain to excitotoxic injury.
The pha~acology of MK-801 and PCP-like compounds irr uiuo appears to be complex. In addition to blocking NMDA responses and NMDA-m~iafed brain injury, they also regulate NMDA recognition site binding in a complex manner. Antagonists of 
